Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group. Forecasting Age-Related Macular Degeneration Through the Year 2050. JAMA Ophthalmol. 2009; 127(4): 533-40. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/422785

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
JAMA Ophthalmol
Publication Date
2009
Authors
Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • Mobile Exam for DR
    Use of a mobile examination for DR screening in Finland decreased visual impairment by 86% in the covered area.  
  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…